The global chemiluminescence immunoassay (CLIA) analyzers market was
valued over US$ 4.4 Bn in 2016 and is projected to register
cumulative annual growth rate (CAGR) of over 6.0% from 2017 to 2025,
according to a new report published by Transparency Market Research
(TMR) titled “Chemiluminescence Immunoassay (CLIA) Analyzers Market
– Global Industry Analysis, Size, Share, Growth, Trends, and
Forecast, 2017–2025”. The report suggests that rising demand for
international accreditations and result comparability by using
high-throughput automated immunoassays is spurring the growth of
chemiluminescence immunoassay (CLIA) analyzers in coming years (2017
to 2025). The North America and Europe are projected to dominate the
global chemiluminescence immunoassay (CLIA) analyzers market in the
coming years owing to increase in manufacturer focus for business
expansion in these regions. Players are continuously developing
multiplexed assay platforms and entering into distribution agreements
to fortify their footprints in the North American and European
markets. Growing adoption of technologically advanced products
manufactured by local manufacturers like Shenzhen New Industries
Biomedical Engineering Co., Ltd. is likely to drive the Asia Pacific
chemiluminescence immunoassay (CLIA) analyzers market. The Asia
Pacific chemiluminescence immunoassay (CLIA) analyzers market is
expected to witness CAGR of over 6.5% from 2017 to 2025.
Request for Sample Copy of Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=31517
The report offers detailed segmentation of global chemiluminescence
immunoassay (CLIA) analyzers market based on product, application,
and end-user. Among the product segment, reagents segment is poised
to account for leading share of the global market during the forecast
period from 2017 to 2025. Factors attributed to the higher share of
the reagent segment in the global market include frequent
replacements leading to increasing usage of reagents when compared to
analyzer platforms. Automated analyzers segment is likely to register
comparatively higher growth rate in terms of value in the global
chemiluminescence immunoassay (CLIA) analyzers market during the
forecast period owing to continuous innovations in the product
technologies by major market players.
Among applications, endocrine disorders segment is projected to hold
dominant share of global chemiluminescence immunoassay (CLIA)
analyzers market during the forecast period and is likely to expand
at CAGR more than 6.0% from 2017 to 2025. Major factors responsible
for the dominance of this segment are continuous innovations in test
offerings and wide product portfolio of major as well as local
manufacturers. For instance, in January, 2017, the world's first
assay to measure free vitamin D was introduced by Future Diagnostics
Solutions and DIAsource Immunoassays SA (Anteo Group). Such
continuous new product launches, along with exponentially rising
patient base in developed as well as developing countries are likely
to drive the segment between 2017 and 2025. According to the National
Institute of Diabetes & Digestive and Kidney Diseases in the
U.S., nearly 4.6% of the U.S. population suffers from hypothyroidism,
which highlights the significant need for advanced testing methods to
diagnose the endocrine disorder. Hepatitis and retrovirus segment,
accounted for more than 10.0% share of global chemiluminescence
immunoassay (CLIA) analyzers market in 2016, in terms of value. It is
anticipated to have substantial growth and account for approximately
12.0% of market share by 2025.
Enquiry for discount on this report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=31517
In terms of value, North America is likely to continue its dominance
in the global chemiluminescence immunoassay (CLIA) analyzers market
throughout the forecast period, owing to significant average selling
prices of automated chemiluminescence immunoassay analyzers, rising
demand from physicians for technologically advanced diagnostic
instruments with enhanced specificity and precision, and favorable
coverage as per the Clinical Laboratory Improvement Amendments for
in-vitro diagnostic procedures in the region. Latin America and
Middle East & Africa are relatively untapped markets having high
growth potential. The governmental cap on prices of analyzers and
group purchasing policies by major multispecialty hospital chains in
this region is further increasing adoption of rental CLIA analyzers
in these regions. Middle East & Africa chemiluminescence
immunoassay (CLIA) analyzers market is characterized with significant
population base demanding affordable care, and rise in governmental
initiatives for early diagnosis of these chronic diseases. For
instance, as per UNAIDS publication in 2016, nearly 65% of the
world’s HIV infected population are present in this region.
The report also provide profiles of leading players operating in
global chemiluminescence immunoassay (CLIA) analyzers market. F.
Hoffmann-La Roche Ltd., Abbott, Siemens Healthineers, and Beckman
Coulter, Inc. (Danaher) are major players operating in the market,
offering products with proprietary technologies, such as F.
Hoffmann-La Roche Ltd.’s products are manufactured using
proprietary electrochemiluminescence technology, while Abbott’s
CLIA analyzers are manufactured using the chemiluminescent
microparticle immunoassay technology. DiaSorin S.p.A. and Shenzhen
New Industries Biomedical Engineering Co., Ltd. are the other major
players in the developed and developing countries, respectively.
Expansion of tests offering in integrated digital diagnostics
platform through partnerships to improve oncology and critical care
treatment is a growing trend in global chemiluminescence immunoassay
(CLIA) analyzers market. For instance, in January 2018, F.
Hoffmann-La Roche Ltd. and GE Healthcare entered into strategic
partnership to develop an industry-first digital platform, which will
provide digital clinical decision support solutions in oncology and
critical care treatment. Other prominent players in the global
chemiluminescence immunoassay (CLIA) analyzers market include Sysmex
Corporation, Randox Laboratories Ltd., Ortho Clinical Diagnostics (a
part of Carlyle Group), and Tosoh Corporation.
Report Overview @
https://www.transparencymarketresearch.com/chemiluminescence-immunoassay-analyzers-market.html
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment